Project Grant R01HL182062
Award Date 8/1/25
Completion Date 5/31/29
Dollars Obligated $760K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Colorado, USA
Similar Awards
- The Regents of the University of Colorado, doing business as the University of Colorado-Denver, was awarded a $723,084 Project Grant by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to support research on the role of the PAR1/IL-17 signaling axis in the development of chronic thromboembolic pulmonary hypertension (CTEPH). The research aims to improve understanding of how different cell types and signaling pathways within chronic thrombi contribute...
- This Project Grant award of $234,000.00 was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to the University of Colorado-Denver to develop "hemostatic red blood cells" (T-RBCs) that can bind to collagen and fibrin to enhance clot formation and stability. The goal is to create a novel technology to address severe, non-compressible bleeding, which is a major cause of mortality worldwide, especially in low-resource settings. The...
- The University of Colorado-Denver received a $553,217 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) on August 15, 2025. The grant supports research on the "HAT-Dependent Control of Cardiac Fibrosis" to investigate the role of epigenetic regulatory proteins in controlling the activation of cardiac fibroblasts and development of cardiac fibrosis, which contributes to diastolic dysfunction and heart failure. The...
- The National Heart Lung and Blood Institute awarded a $503,637 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The University of Kentucky Research Foundation. This grant, awarded on January 15, 2025, supports research to investigate the mechanisms of thrombosis (blood clots) in patients with COVID-19 infection. The key objectives are to measure changes in the hemostatic (clotting) and fibrinolytic (clot-dissolving) systems in COVID-19 patients from initial...
- The federal Project Grant award in the amount of $783,715.00 was granted by the National Heart Lung and Blood Institute, part of the National Institutes of Health, under the Cardiovascular Diseases Research CFDA program (93.837). The award aims to improve the timeliness of care for trauma-induced hemorrhage by comprehensively determining who should be quickly transferred to specialized high-level trauma centers and evaluating state-of-the-art approaches to inform these retriage decisions. The...
- This Project Grant award for $744,880.00 was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to investigate how lactate produced by alveolar epithelial type II cells can shift alveolar macrophages towards an anti-inflammatory phenotype, which could enable therapeutic exploitation of this innate protective mechanism in acute lung injury and acute respiratory distress syndrome. The...
- The National Heart, Lung, and Blood Institute (NHLBI), via the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $564,445 Project Grant to the University of Texas Health Science Center at Houston (UTHealth) to fund research on "Targeting Hypoxia-Inducible Factors (HIFs) for Heart and Lung Disease." The 6-year grant, starting on March 1, 2025 and ending on December 31, 2031, supports three complementary research projects focused on investigating the upstream regulation...
- The Project Grant award titled "FUNCTIONAL COAGULATION AND HEMOSTASIS AFTER INTRACEREBRAL HEMORRHAGE (FIGHT-ICH)" is being provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The Trustees of Columbia University in the City of New York for $829,103.00. The award commences on July 20, 2025 and is set to conclude on April 30, 2030. The grant supports research focused on understanding coagulation and hemostasis processes in patients...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will provide $163,790 to the University of Colorado-Denver over 5 years starting August 1, 2025. The grant will support the research training of Dr. Peter Moore, a physician-scientist, to advance the understanding of macrophage-produced coagulation factor XIII-A and its role in regulating the extracellular matrix and alveolar epithelial repair after acute lung injury....
- The National Heart, Lung, and Blood Institute (NHLBI), through its Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $169,992 Project Grant to the University of Colorado-Denver on September 18, 2025. The grant will fund a 5-year mixed methods study to inform initial antihypertensive prescribing and develop a patient self-titration intervention. The study aims to understand barriers and facilitators to initiating antihypertensive combination therapy versus stepped...